-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Short Interest in PureTech Health Plc (NASDAQ:PRTC) Declines By 63.6%
Short Interest in PureTech Health Plc (NASDAQ:PRTC) Declines By 63.6%
PureTech Health plc (NASDAQ:PRTC – Get Rating) saw a significant decrease in short interest in the month of December. As of December 15th, there was short interest totalling 400 shares, a decrease of 63.6% from the November 30th total of 1,100 shares. Based on an average daily volume of 2,700 shares, the short-interest ratio is currently 0.1 days.
PureTech Health Stock Performance
Shares of PureTech Health stock remained flat at $32.77 during trading on Wednesday. 12 shares of the stock were exchanged, compared to its average volume of 1,771. The stock's 50-day moving average is $31.01 and its two-hundred day moving average is $27.44. PureTech Health has a one year low of $18.15 and a one year high of $43.57.
Get PureTech Health alerts:Institutional Trading of PureTech Health
A hedge fund recently raised its stake in PureTech Health stock. AWM Investment Company Inc. lifted its position in shares of PureTech Health plc (NASDAQ:PRTC – Get Rating) by 2,100.0% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 660,000 shares of the company's stock after purchasing an additional 630,000 shares during the period. AWM Investment Company Inc. owned 2.32% of PureTech Health worth $2,513,000 as of its most recent SEC filing. 0.25% of the stock is currently owned by institutional investors and hedge funds.
About PureTech Health
(Get Rating)PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions.
Featured Stories
- Get a free copy of the StockNews.com research report on PureTech Health (PRTC)
- The Top Three Stocks Analysts Say To Buy
- Can Dick's Sporting Goods Stock Score Another Win In Q4?
- Yum! Brands Looks Tasty in 2023
- Why Did Immutep Ltd Stock Soar Recently?
- 3 Industrial Stocks to Help Build Your 2023 Watchlist
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.
PureTech Health plc (NASDAQ:PRTC – Get Rating) saw a significant decrease in short interest in the month of December. As of December 15th, there was short interest totalling 400 shares, a decrease of 63.6% from the November 30th total of 1,100 shares. Based on an average daily volume of 2,700 shares, the short-interest ratio is currently 0.1 days.
PureTech Health Plc(纳斯达克代码:PRTC-GET Rating)12月份空头股数销量大幅下降。截至12月15日,空头股数共有400股,比11月30日的1100股减少了63.6%。以日均成交量2,700股计算,短息比率目前为0.1天。
PureTech Health Stock Performance
PureTech Health股票表现
Shares of PureTech Health stock remained flat at $32.77 during trading on Wednesday. 12 shares of the stock were exchanged, compared to its average volume of 1,771. The stock's 50-day moving average is $31.01 and its two-hundred day moving average is $27.44. PureTech Health has a one year low of $18.15 and a one year high of $43.57.
在周三的交易中,PureTech Health的股价持平于32.77美元。该股共交换了12股,而其平均成交量为1,771股。该股的50日移动均线切入位为31.01美元,200日移动均线切入位为27.44美元。PureTech Health的一年低点为18.15美元,一年高位为43.57美元。
Institutional Trading of PureTech Health
PureTech Health的制度性交易
A hedge fund recently raised its stake in PureTech Health stock. AWM Investment Company Inc. lifted its position in shares of PureTech Health plc (NASDAQ:PRTC – Get Rating) by 2,100.0% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 660,000 shares of the company's stock after purchasing an additional 630,000 shares during the period. AWM Investment Company Inc. owned 2.32% of PureTech Health worth $2,513,000 as of its most recent SEC filing. 0.25% of the stock is currently owned by institutional investors and hedge funds.
一家对冲基金最近增持了PureTech Health股票。AWM Investment Company Inc.在最近一次向美国证券交易委员会披露的信息中称,该公司在第二季度将其在PureTech Health plc(纳斯达克代码:PRTC-GET Rating)的股票持仓上调了2,100.0%。该公司在此期间额外购买了630,000股后,拥有66,000股公司股票。截至最近提交的美国证券交易委员会申请文件,AWM Investment Company Inc.持有PureTech Health 2.32%的股份,价值2,513,000美元。该股目前由机构投资者和对冲基金持有0.25%的股份。
About PureTech Health
关于PureTech Health
PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions.
PureTech Health plc是一家临床阶段的生物治疗公司,在美国发现、开发和销售治疗炎症、纤维化和免疫、顽固性癌症、淋巴和胃肠道、神经和神经心理以及其他疾病的药物。该公司提供靶向M胆碱乙酰胆碱受体的KarXT,用于治疗阿尔茨海默病的精神分裂症和精神病;用于治疗雄激素性脱发、上皮老化和其他疾病的再生生物学平台;用于治疗慢性和急性炎症性疾病的免疫调节平台;用于从人体微生物群中分离出基于特定细菌群的口服疗法;以及用于治疗与抑郁症、多发性硬化症、COVID后和ICU以及癌症相关疾病相关的认知功能障碍的疗法。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on PureTech Health (PRTC)
- The Top Three Stocks Analysts Say To Buy
- Can Dick's Sporting Goods Stock Score Another Win In Q4?
- Yum! Brands Looks Tasty in 2023
- Why Did Immutep Ltd Stock Soar Recently?
- 3 Industrial Stocks to Help Build Your 2023 Watchlist
- 免费获取StockNews.com关于PureTech Health(PRTC)的研究报告
- 分析师认为最值得买入的三只股票
- Dick‘s Sports Goods Stock能否在第四季度再获胜利?
- 好吃!品牌在2023年看起来很美味
- 为什么Immutep公司的股票最近飙升了?
- 帮助你建立2023年观察名单的3只工业股票
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.
获得PureTech HealthDaily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对PureTech Health和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧